In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biodesix to market VeriStrat companion test for Aveo’s ficlatuzumab

Executive Summary

Biodesix Inc. (multivariate testing in oncology) agreed to market its VeriStrat as a companion diagnostic to cancer company Aveo Pharmaceuticals Inc.’s ficlatuzumab, an anti-hepatocyte growth factor antibody in Phase II for non-small cell lung cancer (NSCLC). VeriStrat is a serum proteomic blood test that stratifies NSCLC patients based on the expected outcome with EGFR tyrosine kinase inhibitor treatment.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register